Turning a stroke into a TIA: curative thrombolysis with combined intravenous and intra-arterial tPA

David J. Gladstone, MD,*† Richard I. Aviv, MRCP;‡ Babak Jahromi, MD;‡ Sandra E. Black, MD,*† Devra Baryshnik, MD,* Rochelle Caratao, RN,* Allan J. Fox, MD‡

Introduction

In Canada, intravenous tissue plasminogen activator (tPA) has become standard care for eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.¹ However, with intravenous tPA, the chance of successful angiographic recanalization is low for proximal large artery occlusions (only 9% for carotid occlusions and 35% for M1-MCA [M1 segment middle cerebral artery] occlusions) and best for distal branch occlusions (54% for M2-MCA occlusions and 66% for M3-MCA occlusions).² Therefore, for patients with severe stroke, there is growing

Key words: acute ischemic stroke; intravenous tPA; intra-arterial tPA; IV–IA thrombolytic approach
interest in moving beyond IV tPA alone and combining it with IA thrombolysis or techniques for mechanical clot removal or disruption.

Case report

Toronto emergency medical services paramedics transported a 52-year-old previously healthy woman to our regional stroke centre under an acute stroke prehospital redirect protocol 29 minutes after symptom onset. Examination revealed signs of a major right MCA stroke: forced gaze deviation to the right, complete left hemiplegia, hemisensory loss, and severe hemispatial neglect (anosognosia and extinction to tactile, visual and auditory stimuli). The National Institutes of Health Stroke Scale (NIHSS) score was 17 and the ECG showed rapid atrial fibrillation. Computed tomography (CT) 30 minutes after arrival demonstrated a hyperdense MCA, and CT angiography confirmed a 1.4-cm M1 segment MCA occlusion (Fig. 1). Early ischemic changes were already present (Fig. 1 [left]) but a larger area of potentially salvageable “tissue at risk” was identified on CT perfusion imaging (Fig. 2).

A 0.6-mg/kg intravenous dose of tPA (alteplase) was ad-
ministered, with 15% given as a bolus, followed by a 30-minute infusion (symptom onset-to-needle time was 89 min). The patient was transported to the angiography suite 105 minutes post-onset, where a diagnostic angiogram confirmed that the M1 segment occlusion was still present (thrombolysis in myocardial infarction [TIMI] classification 0) (Fig. 3 [left]). An Excelsior 1018 microcatheter (Boston Scientific, Redmond, Wash.) was advanced over a Transend EX platinum (Boston Scientific) 0.36-mm wire through the thrombus into the M2 segment. After imaging the distal circulation, the catheter was withdrawn while a total of 14 mg of alteplase was administered by intermittent slow injections beyond and directly into the thrombus. The patient experienced a focal epileptic seizure toward the end of the procedure, correlating with reperfusion.

Following the procedure, complete recanalization was achieved (TIMI 3) (Fig. 3 [right]) with immediate dramatic clinical recovery. There were no clinical complications. Post-angiography CT scan showed contrast enhancement of the right basal ganglia, which cleared the following day. A focal area of contrast extravasation was also present in the posterior putamen, compatible with blood–brain barrier breakdown; a susceptibility-weighted magnetic resonance imaging study later confirmed asymptomatic microhemorrhage. The patient was ambulating the next day and discharged home with no detectable neurologic deficit. Re-examination 3 weeks later confirmed a complete neurologic recovery: NIHSS score 0, Folstein Mini Mental State Examination 30/30, Barthel Index 100/100, and normal performance on the Sunnybrook Neglect Assessment Procedure for hemispatial inattention. She was able to resume all her independent daily activities. She was prescribed oral anticoagulation for secondary stroke prevention.

**Discussion**

This case demonstrates that acute stroke thrombolysis can be very effective in the appropriate candidate. Without treatment, spontaneous recovery would not have been expected given the extent of the proximal MCA thrombus and the early neuroimaging signs of evolving infarction.

A hyperdense MCA sign on baseline CT correlates with severe stroke and predicts a poor outcome, even after treatment with IV tPA. We used an acute stroke imaging protocol consisting of plain head CT, CT angiography, CT perfusion, and post-contrast head CT (total scan time approximately 2 min), which can facilitate patient selection for thrombolysis by providing rapid information about the vascular lesion, extent of infarction and presence of potentially salvageable brain tissue.

The PROACT II Trial demonstrated that IA thrombolysis with prourokinase within 6 hours is an efficacious treatment for MCA occlusions, with improved outcomes in treated patients compared with placebo in terms of recanalization rate (66% v. 18%) and favourable clinical outcome on the Rankin Scale (40% v. 25%), but a higher rate of symptomatic intracranial hemorrhage (10% v. 2%). However, IA thrombolysis is available only at selected stroke centres as an “off-label” intervention. Our preferred term for this treatment is “intra-clot lysis” to distinguish it from infusion of an intra-arterial thrombolytic proximal to the target occlusion, for example, from the carotid artery in the neck.

Because favourable outcomes from tPA are highly depen-
dent on shorter stroke onset-to-needle times, immediate administration of a partial dose of IV tPA first (two-thirds of the standard dose) has the advantage of initiating treatment quickly while the patient is being transferred for angiography for direct intra-cloot lysis. The EMS Bridging Trial, which randomized 35 patients, showed that the IV–IA combination approach improved recanalization rates compared with IA treatment alone. Safety and feasibility of this combined IV–IA approach was further demonstrated in an IMS study of 80 patients with a 6.6% symptomatic intracranial hemorrhage rate, and in 2 smaller prospective studies.

The IMS-III Trial (www.uc.edu/news/NR.asp?id=3136) aims to provide more definitive investigation about the efficacy and safety of the combined IV–IA thrombolytic approach.

Conclusions

Many centres are gaining experience using the combined IV–IA thrombolytic approach as a treatment option for carefully selected individuals with severe acute ischemic stroke, although it remains an investigational procedure that awaits further study in randomized trials.

Acknowledgements: We gratefully acknowledge the rapid response and coordinated efforts of the following individuals: Warren Estabrooks for recognizing the patient’s stroke symptoms and activating 9-1-1; Aidan Moore, Jason Molyneaux, Carol Hetherington and Susan Kennedy from Toronto EMS who responded to the call; emergency department nurses Jennifer Dermid, Cristina Hincapie and Liz Pelley; Deanna Reynold and our team of CT technologists; angiography technologist Michelle Fraser and nurse Naiia Devraj; and critical care unit nurse Ellie Stein.

Dr. Gladstone gratefully acknowledges support from the Heart and Stroke Foundation Centre for Stroke Recovery, the Department of Medicine, Sunnybrook and Women’s College Health Sciences Centre, and the Department of Medicine, University of Toronto.

Competing interests: None declared.

References


Correspondence to: Dr. David Gladstone, Division of Neurology and Regional Stroke Centre, A442 Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Ave., Toronto ON M4N 3M5